Lightnews — Scholar-powered news

Reposted by Brennan Kahan

Jack Wilkinson @jdwilko.bsky.social · 7d

Introductory online INSPECT-SR workshop. November 6th, 12-2pm UK-time. Free, places limited. BOOK: www.trybooking.com/uk/events/la...

Introduction to INSPECT-SR Training Workshop November

An introductory 2-hour online workshop will introduce participants to the INSPECT-SR tool for assessing trustworthiness of randomised controlled...

www.trybooking.com

1 6 5

Reposted by Brennan Kahan

Journal of Clinical Epidemiology @jclinepi.bsky.social · Aug 20

The number needed to treat: It is time to bow out gracefully - Journal of Clinical Epidemiology www.jclinepi.com/article/S089...

The number needed to treat: It is time to bow out gracefully

The number needed to treat (NNT) has statistical and methodological limitations that make it unhelpful in the context of developing clinical practice guidelines and policy decisions.It is not unusual ...

www.jclinepi.com

5 5

Reposted by Brennan Kahan

Marion Campbell @marionkcampbell.bsky.social · Aug 18

There has been a lot of debate recently about the promise of real world data - the routine (observational) data collected on patients eg treatments received, clinical outcomes etc – for estimating treatment effects. But can they deliver? 1/9
#MethodologyMonday #123

2 16 28

Reposted by Brennan Kahan

Stepped Wedgehog @steppedwedgehog.bsky.social · Aug 5

Improving the design of staggered implementation cluster randomised trials qualitysafety.bmj.com/content/earl...

Grand rounds in methodology: improving the design of staggered implementation cluster randomised trials

The stepped-wedge cluster randomised trial is a popular design in implementation and health services research. All clusters, such as clinics or hospitals, start in the control state, and gradually swi...

qualitysafety.bmj.com

3 3

Reposted by Brennan Kahan

Marion Campbell @marionkcampbell.bsky.social · Jul 21

We often now hear the term “Bayesian borrowing” in trials. But what is Bayesian borrowing and what are the pros and cons around its use? 1/6
#MethodologyMonday #122

1 11 20

Reposted by Brennan Kahan

Gary Collins @gscollins.bsky.social · Jul 16

NEW PAPER in @bmj.com "Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide"

--> www.bmj.com/content/390/...

#methodologymatters #StatsSky #EpiSky

1 17 51

Brennan Kahan @brennankahan.bsky.social · Jul 15

If outcome = "no. of antibiotic prescriptions" and more people in one arm get LT antibiotics (which presumably precludes further prescriptions?), this does seem like a challenge.

Could of course be good reasons for it - does highlight importance of estimands (along with justifications for choice)!

Brennan Kahan @brennankahan.bsky.social · Jul 15

Think they've used a treatment policy strategy (ie were interested in the effect of Hiprex vs placebo whether or not people started on suppressive antibiotics later).

I don't know enough about the area to say if this is sensible, but if suppressive antibiotics are part of usual care, it may be?

1

Reposted by Brennan Kahan

Jack Wilkinson @jdwilko.bsky.social · Jul 9

What's that? The target trial emulation obtained the same answer as the RCT? Wow, I guess RCTs are generalisable after all! Perhaps we should perform them rather than using interventions on hundreds of thousands of people before we know whether or not they work, then doing a TTE?

5 3 18

Reposted by Brennan Kahan

Tim Morris @timpmorris.bsky.social · Jul 9

Reckon I can submit this as a figure for a paper?

Goose chase meme. Goose asks "Unbiased for what estimand?" then yells "Unbiased for what!!"

4 15 100

Reposted by Brennan Kahan

Tim Morris @timpmorris.bsky.social · Jul 7

New post: “Marginal” and “conditional” are relative descriptions of an estimand

Foreground text says “Marginal” and “conditional” are relative descriptions of an estimand
In the background is a smokey mollusc

2 3 13

Brennan Kahan @brennankahan.bsky.social · Jul 1

New paper posted on Arxiv: "When do composite estimands answer non-causal questions?"

This can happen more often than you think, and can have a dramatic impact on trial results (e.g. a false-positive rate of almost 90%)

arxiv.org/abs/2506.22610 @timpmorris.bsky.social

When do composite estimands answer non-causal questions?

Under a composite estimand strategy, the occurrence of the intercurrent event is incorporated into the endpoint definition, for instance by assigning a poor outcome value to patients who experience th...

arxiv.org

6 12

Reposted by Brennan Kahan

UK CTU Network @ukcrc-ctu.org.uk · Jun 17

The CONSORT 2025 Statement is here. Essential reading for those involved in the reporting & reviewing of randomized trials.

We're proud to see so many #UKCTUNetwork units & individual researchers contributing to this crucial update!

🔗 tinyurl.com/yc3cbh33

#CONSORT2025 #ResearchTransparency

CONSORT 2025 Statement

This Special Communication introduces the updated Consolidated Standards of Reporting Trials (CONSORT) 2025 statement, which includes substantive and structural changes to account for recent methodolo...

jamanetwork.com

5 8

Reposted by Brennan Kahan

Sara Conroy, PhD @episconroy.bsky.social · Jun 16

Would like to add… there are guidelines for all types of studies… www.equator-network.org/reporting-gu...

2 5

Reposted by Brennan Kahan

Darren Dahly @statsepi.bsky.social · Jun 15

Please people. It's not hard. In fact, it makes your life easier. And when you don't use CONSORT, you look like a novice.

JAMA @jama.com · Jun 15

Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomized trials to ensure that trial reports are clear and transparent.

Learn more in this Special Communication.

https://ja.ma/3TlnKQe

CONSORT 2025 Statement
Updated Guideline for Reporting Randomized Trials

1 12 47

Reposted by Brennan Kahan

JAMA @jama.com · Jun 15

Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomized trials to ensure that trial reports are clear and transparent.

Learn more in this Special Communication.

https://ja.ma/3TlnKQe

29 51

Reposted by Brennan Kahan

Richard Hooper @richardhooper.bsky.social · Jun 13

Stepped wedge devotees step up, and cluster enthusiasts get ready to cluster: it's conference time again.

Stepped Wedgehog @steppedwedgehog.bsky.social · Jun 13

📢 The 11th annual meeting on Current Developments in Cluster Randomised Trials & Stepped Wedge Designs will take place 18/19 November 2025 in Birmingham UK.

Abstract submission is open, deadline for submission 11 July 2025 forms.gle/jS83TAKhs4U8.... Info on registration etc to follow!

4 6

Reposted by Brennan Kahan

MRC Clinical Trials Unit at UCL @mrcctu.bsky.social · Jun 9

🆕New CONSORT & SPIRIT 2025 Guidelines

Our colleagues helped shape these updates, making #ClinicalTrial reporting more transparent & useful for everyone.

Key changes:
✔️More open science
✔️Better reporting of harms & missing data
✔️Greater harmonisation between guidelines

More info: buff.ly/HC1rx31

New CONSORT & SPIRIT 2025 Guidelines Published | MRC Clinical Trials Unit at UCL

www.mrcctu.ucl.ac.uk

8 11

Reposted by Brennan Kahan

Gary Collins @gscollins.bsky.social · Jun 2

NEW PAPER "Importance of sample size on the quality and utility of AI-based prediction models for healthcare"

www.thelancet.com/journals/lan...

We discuss seven reasons why inadequate sample size negatively affects model training, evaluation, and performance.

#StatsSky #machinelearning #AI

1 2 9

Reposted by Brennan Kahan

Marion Campbell @marionkcampbell.bsky.social · Jun 2

One of the trial designs that has been cropping up in my discussions recently is the cluster randomised crossover, or CRXO, design. But when is it best used & what are the key issues to look out for? 1/7
#MethodologyMonday #119

3 10 21

Brennan Kahan @brennankahan.bsky.social · May 29

New 3-post for a research/senior research fellow to work on adaptive longitudinal cluster randomised trials in Melbourne.

Interesting work with a great research group.

careers.pageuppeople.com/513/cw/en/jo...

Job Search

careers.pageuppeople.com

3 3

Reposted by Brennan Kahan

Rachel Phillips @rachpips.bsky.social · May 28

Next Thursday, June 5th at 1pm (BST) we host our 4th webinar in our adverse event special series. Rayan Taher & Jenny Yiend will present their work on developing a process for assessing the safety of a digital mental health intervention & gaining regulatory approval. Register here: lnkd.in/eaW3MQrB

Microsoft Forms

forms.microsoft.com

2 3 5

Reposted by Brennan Kahan

Matteo Quartagno @matteoq21.bsky.social · May 27

Hot off the press:
bmcmedresmethodol.biomedcentral.com/articles/10....

In this we confirm empirically some theoretical results about using different summary measures in non-inferiority trials with survival outcomes. tldr: RMST beats HR.

Summary measures in non-inferiority clinical trials with a time-to-event outcome: an empirical comparison of power - BMC Medical Research Methodology

Background Time-to-event data is commonly used in non-inferiority clinical trials. While the hazard ratio is a popular summary measure in this context, the difference in restricted mean survival time ...

bmcmedresmethodol.biomedcentral.com

1 2 2

Reposted by Brennan Kahan

Rachel Phillips @rachpips.bsky.social · May 15

Read the original paper here: trialsjournal.biomedcentral.com/articles/10....

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines - Trials

Background The SAVVY project aims to improve the analyses of adverse events (AEs) in clinical trials through the use of survival techniques appropriately dealing with varying follow-up times and compe...

trialsjournal.biomedcentral.com

1 1

Reposted by Brennan Kahan

Rachel Phillips @rachpips.bsky.social · May 15

Next week (May 22nd) we host our third webinar in our adverse event special series. Regina Stegherr will be discussing the SAVVY project which aims to improve the analyses of AEs in clinical trials using survival methods to handle varying follow-up & competing events. Register here: lnkd.in/eaW3MQrB

This link will take you to a page that’s not on LinkedIn

lnkd.in

1 1 1